Covagen AG (acquired by Johnson & Johnson)
Creating the next generation of biologics
Covagen is a privately held company pioneering the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Due to their favorable biophysical properties, Fynomers with different binding specificities can be combined in a single molecule, thus creating drugs with new mechanisms of action.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
17.04.2015
Nine hot start-ups, 400 visitors and Joe Jimenez (startupticker.ch)
25.08.2014
Janssen Affiliate Cilag GmbH International Acquires Covagen AG (startupticker.ch)
05.05.2014
Covagen’s first clinical trials (startupticker.ch)
19.02.2014
Covagen Adds Baxter Ventures as Investor (startupticker.ch)
No Jobs
Documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Leaders Technology
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
>>Venture>>
The venture business plan competition takes place every year and combines a competition, learning events and contact form in one. It is an initiative of the ETH Zurich, CTI and McKinsey.
CTI Start-up Label
CTI Start-up enables entrepreneurs to realize their innovative idea professionally.
In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.
Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.
CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.
ETH Spin-off
http://www.vpf.ethz.ch/transfer/firmgruend/spinoff_list/by_years/2009
Covagen AG (acquired by Johnson & Johnson)
Creating the next generation of biologics
Website:
www.covagen.com
Johnson & Johnson
Headquarter:
Zürich-Schlieren
Foundation Date:
January 2007
Technology:
- Biotech
Sectors:
- Antibodies
- Cancer
- Drug development platforms
- Drug discovery
- Inflammation
- Protein drugs
Support received
